<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18579984</article-id><article-id pub-id-type="pmc">2636159</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_4_269_41410</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Post-penetrating keratoplasty glaucoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Dada</surname><given-names>Tanuj</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Aggarwal</surname><given-names>Anand</given-names></name><degrees>MD, DNB</degrees></contrib><contrib contrib-type="author"><name><surname>Minudath</surname><given-names>KB</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Vanathi</surname><given-names>M</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Choudhary</surname><given-names>Sunil</given-names></name><degrees>MD, DNB</degrees></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Viney</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Sihota</surname><given-names>Ramanjit</given-names></name><degrees>MD, FRCS</degrees></contrib><contrib contrib-type="author"><name><surname>Panda</surname><given-names>Anita</given-names></name><degrees>MD, FRCS</degrees></contrib></contrib-group><aff>Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India</aff><author-notes><corresp id="cor1">Correspondence to Dr. Tanuj Dada, Associate Professor, Dr. RajendraPrasad Centre for Ophthalmic Sciences, New Delhi - 110 029, India.Email: <email>tanujdada@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2008</year></pub-date><volume>56</volume><issue>4</issue><fpage>269</fpage><lpage>277</lpage><history><date date-type="received"><day>26</day><month>8</month><year>2006</year></date><date date-type="accepted"><day>03</day><month>8</month><year>2007</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Post-penetrating keratoplasty (post-PK) glaucoma is an important cause of irreversible visual loss and graftfailure. The etiology for this disorder is multifactorial, and with the use of new diagnostic equipment, it isnow possible to elucidate the exact pathophysiology of this condition. A clear understanding of the variousmechanisms that operate during different time frames following PK is essential to chalk out the appropriatemanagement algorithms. The various issues with regard to its management, including the putative risk factors,intraocular pressure (IOP) assessment post-PK, difficulties in monitoring with regard to the visual fieldsand optic nerve evaluation, are discussed. A step-wise approach to management starting from the medicalmanagement to surgery with and without metabolites and the various cycloablative procedures in cases of failedfiltering procedures and excessive perilimbal scarring is presented. Finally, the important issue of minimizingthe incidence of glaucoma following PK, especially through the use of oversized grafts and iris tighteningprocedures in the form of concomitant iridoplasty are emphasized. It is important to weigh the risk-benefitratio of any modality used in the treatment of this condition as procedures aimed at IOP reduction, namelytrabeculectomy with antimetabolites, and glaucoma drainage devices can trigger graft rejection, whereascyclodestructive procedures can not only cause graft failure but also precipitate phthisis bulbi. Watchfulexpectancy and optimal time of intervention can salvage both graft and vision in this challenging condition.</p></abstract><kwd-group><kwd>Glaucoma</kwd><kwd>penetrating keratoplasty</kwd><kwd>iridoplasty</kwd><kwd>trabeculectomy</kwd></kwd-group></article-meta></front><body><p>Glaucoma following penetrating keratoplasty (PK) is one ofthe most common cause for irreversible visual loss<xref ref-type="bibr" rid="ref1">1</xref> and thesecond leading cause for graft failure<xref ref-type="bibr" rid="ref2">2</xref> [<xref ref-type="fig" rid="F1">Fig. 1</xref>] afterrejection. Post-PK glaucoma is a significant clinical problem because of itsfrequency of occurrence, difficulty in diagnosis and monitoring,and complexity of management.<xref ref-type="bibr" rid="ref3">3</xref> An increase in intraocularpressure (IOP) at any time after PK leads to a significantendothelial cell loss, with dire consequences as the endothelialreserve is already low. Timely diagnosis of post-PK glaucomawith initiation of appropriate treatment is mandatory to preserveoptimal graft clarity and optic nerve head function.<xref ref-type="bibr" rid="ref2">2</xref></p><p>Post-PK glaucoma is defined as an elevated IOP greater than21 mmHg, with or without associated visual field loss or opticnerve head changes. Diagnostic difficulty arises due to errors intonometry recordings of a thick or astigmatic corneal graft.<xref ref-type="bibr" rid="ref4">4</xref> Inaddition, it is often not possible to assess adequately the opticnerve and visual field before surgery or in the immediate post-operative period because of preoperative media opacificationand post-operative corneal distortion with high astigmatism,respectively.<xref ref-type="bibr" rid="ref4">4</xref></p><p>It was only in the 1960s, with the development of instrumentsthat allowed routine monitoring of IOP after PK, that theproblem of post-PK glaucoma was recognized. In 1969, Irvineand Kaufman<xref ref-type="bibr" rid="ref5">5</xref> first reported the high incidence of increasedIOP following PK. They reported a mean maximum pressureof 40 mmHg in aphakic transplants and 50 mmHg in combinedtransplants and cataract extraction in the immediate post-operative period. Since then, various authors have reportedthe incidence of glaucoma following PK to be from 9 to 31%in the early post-operative period<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref> and from 18 to 35% in thelate post-operative period.<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref8">8</xref></p><p>The purpose of the present review is to highlight themagnitude of the problem. The etiology, risk factors, diagnosticassessment and management options are reviewed andthe prognosis as reported in the literature is highlighted.A PubMed/Medline search using keywords like penetratingkeratoplasty and glaucoma, or glaucoma following PK wasdone over the last 30 years. The search was limited to articlesin English. For articles in other languages, only the abstract inEnglish was taken for reference.</p><sec sec-type=""><title>Etiology</title><sec><title>Risk factors for glaucoma in patients undergoing PK include:</title><p><list list-type="bullet"><list-item><p>Aphakic and pseudophakic bullous keratopathy<xref ref-type="bibr" rid="ref7">7</xref></p></list-item><list-item><p>Mesodermal dysgenesis<xref ref-type="bibr" rid="ref6">6</xref></p></list-item><list-item><p>Irido-corneal-endothelial syndrome</p></list-item><list-item><p>Pre-existing glaucoma<xref ref-type="bibr" rid="ref3">3</xref></p></list-item><list-item><p>Perforated corneal ulcer<xref ref-type="bibr" rid="ref9">9</xref></p></list-item><list-item><p>Adherent leukoma</p></list-item><list-item><p>Previous PK<xref ref-type="bibr" rid="ref9">9</xref></p></list-item><list-item><p>Post-traumatic cases<xref ref-type="bibr" rid="ref7">7</xref></p></list-item><list-item><p>Combined PK and cataract extraction</p></list-item><list-item><p>Performance of vitrectomy during PK</p></list-item></list></p></sec><sec><title>Indications for PK and associated rates of chronic post-PKglaucoma</title><p>Goldberg <italic>et al</italic>.<xref ref-type="bibr" rid="ref3">3</xref> reported a 29% incidence of increased IOP in theearly post-operative period and 30% in the late post-operativeperiod in patients with aphakic bullous keratopathy. Theyreported that the incidence of increased IOP is higher in patientswith repeat grafts, both in the early (45%) and late post-operativephase (52%) and those with pre-existing glaucoma (71% of allpatients with pre-existing glaucoma developed elevated IOPin the early post-operative course).<xref ref-type="bibr" rid="ref3">3</xref> Kirkness <italic>et al</italic>.<xref ref-type="bibr" rid="ref9">9</xref> reporteda higher incidence of glaucoma in patients undergoingPK following corneal perforation, especially those followingsuppurative keratitis, due to peripheral anterior synechia (PAS)formation and secondary angle closure. As seen in <xref ref-type="table" rid="T1">Table 1</xref>, therates of chronic glaucoma after PK differ significantly basedon the indication for PK (from a low of 0-12% for keratoconusto a high of 75% after infectious keratitis).</p></sec></sec><sec sec-type=""><title>Pathophysiology</title><p>Pathophysiology of post-PK glaucoma is multifactorial[<xref ref-type="table" rid="T2">Table 2</xref>] and may be related to distortion of the angle withcollapse of the trabecular meshwork, suturing technique,post-operative inflammation, use of corticosteroids, PASformation and pre-existing glaucoma. Olson and Kaufman,<xref ref-type="bibr" rid="ref8">8</xref>using a mathematical model, proposed that the elevated IOPfollowing PK in an aphakic patient might be the result of angledistortion secondary to a compressed tissue in the angle. Edemaand inflammation after surgery lead to further compromise inthe trabecular meshwork function, and the situation is furtheraggravated by angle distortion. Factors that contribute to angledistortion include tight suturing, long bites (more compressedtissue), larger trephine sizes, smaller recipient corneal diameterand increased peripheral corneal thickness. The followingsurgical variables reduce angle compression:</p><p><list list-type="bullet"><list-item><p>Less tight sutures</p></list-item><list-item><p>Deep sutures</p></list-item><list-item><p>Short sutures</p></list-item><list-item><p>Suture bites equal on either side of wound</p></list-item><list-item><p>Smaller sized grafts</p></list-item><list-item><p>Donor corneas larger than that of the recipient</p></list-item><list-item><p>Thinner recipient corneas</p></list-item><list-item><p>Larger overall corneal diameter</p></list-item></list></p><p>On the other hand, Zimmerman <italic>et al.</italic><xref ref-type="bibr" rid="ref10">10</xref> proposed thatmechanical collapse of the trabecular meshwork in aphakic graftsis the main problem leading to glaucoma. They postulated thatthe trabeculum needs posterior fixation afforded by the ciliarybody-lens support system and an anterior support afforded bythe Descemet&#x02032;s membrane. In aphakia, the posterior support isrelaxed with the removal of the lens. After PK, the Descemet&#x02032;smembrane is incised, which leads to a relaxation of the anteriorsupport. Both these factors lead to a partial trabecular collapseand obstruction of aqueous outflow. Supporting this theory,Zimmerman <italic>et al</italic>.<xref ref-type="bibr" rid="ref11">11</xref> reported that oversized donor buttons(0.5 mm larger than the host bed) in aphakic patients reducedthe incidence of glaucoma. The effect was more obvious whenan 8-mm donor button was used in a 7.5-mm host bed. Retainedviscoelastic material is another important cause for increasedIOP in the early post-operative period, especially with the use ofsodium hyaluronate 2.3% (Healon 5) or Healon GV (1.4%) andits combination with chondroitin sulfate (Viscoat) used duringPK. One has to be cautious when these high viscosity agents areused because they can clog the trabecular meshwork, leadingto a severe post-operative IOP spike. Complete removal mustbe done at the end of surgery.</p><p>The main cause for late post-PK glaucoma is synechial angleclosure with the degree of synechial closure strongly correlatedwith the need for surgery.<xref ref-type="bibr" rid="ref12">12</xref> A floppy atrophic iris may also leadto a higher incidence of PAS formation, which can be preventedby iris suturing or iridoplasty.<xref ref-type="bibr" rid="ref13">13</xref></p></sec><sec sec-type=""><title>Diagnosis</title><p>Accurate measurement of IOP, assessment of visual fields andneuroretinal structures are often not possible before PK dueto the primary corneal disease. This often leads to an inabilityto diagnose pre-existing glaucomatous optic neuropathy.Following PK, changes in corneal thickness, post-operativeastigmatism and refractive changes often preclude reliable post-operative assessment of IOP, disc and visual field. Extra timeneeds to be devoted for such patients with the main emphasison stereoscopic optic nerve head evaluation under mydriasis.Gonioscopy may be performed to view the site and extent ofPAS [<xref ref-type="fig" rid="F1">Fig. 1</xref>]. The ideal way is to take disc photographs at thefirst examination and serially repeat them at least once a yearto detect if there is any progression of the glaucomatous opticneuropathy.</p><p>The diagnosis of post-PK glaucoma is primarily based onIOP measurements in the early post-operative period, and onIOP, optic disc change and progressive visual field changesin the late post-operative period. IOP in the early post-operative period, when the corneal surface is irregular, canbe measured with the Mackay-Marg electronic applanationtonometer,<xref ref-type="bibr" rid="ref14">14</xref> the pneumatic applanation tonometer, thetono-pen, or recently the dynamic contour tonometer (DCT),independent of the corneal thickness. If the graft surface issmooth with an intact epithelium and regular mires can beobtained, then Goldmann applanation can be used to measurethe IOP. Marked corneal astigmatism causes an ellipticalfluorescein pattern. To obtain an accurate reading withthe Goldmann applanation tonometer, the clinician shouldrotate the prism so that the red mark on the prism holderis set at the least curved meridian of the cornea (along thenegative axis). Alternately, two pressure readings, taken 90degrees apart, can be averaged. The accuracy of applanationtonometry is reduced in certain situations, such as cornealedema, scars, blood staining, or any condition that thickensor alters the corneal elasticity.<xref ref-type="bibr" rid="ref15">15</xref> Corneal epithelial edemaand stromal edema predispose to inaccurately low readings,whereas pressure measurements taken over a corneal scarwill be falsely high. While measuring IOP with Goldmannapplanation tonometer that is standardized for a centralcorneal thickness (CCT) of 520 &#x000b5;, overestimation of IOP mayoccur due to an increase in the corneal thickness.</p><p>In cases with complete tarsorrhaphy, the IOP can be estimatedby digital palpation,<xref ref-type="bibr" rid="ref16">16</xref> although new tonometers that measure IOPthrough the lid (Proview Phosphene Tonometer) are available.In such cases, measuring the IOP in the normal eye using theGoldmann applanation tonometer and then performing digitalpalpation gives a better estimate of the IOP.</p><sec><title>Ultrasound biomicroscopy</title><p>Ultrasound biomicroscopy is useful to assess the angle andestablish the cause for post-PK glaucoma, especially in eyeswith a failed graft where anterior segment details are notclearly visible. The extent of irido-corneal adhesions, locationof intraocular lens (IOL), phakic/aphakic status, anteriorchamber (AC) depth, angle width and corneal thickness canbe determined with this technology. Moreover, UBM can be ofuse to the anterior segment surgeon by providing preoperativedata regarding the anterior segment anatomy, especially withregard to the presence of irido-corneal adhesions and to guidethe surgeon regarding extra precautions to be taken in suchareas to prevent or minimize inadvertent iris damage duringPK. It also aids the glaucoma surgeon in planning the site fortrabeculectomy or a glaucoma drainage device (GDD).</p><p>In a UBM study undertaken by the lead investigator,<xref ref-type="bibr" rid="ref17">17</xref>UBM findings in 31 eyes with post keratoplasty glaucomawere reported. Indication for keratoplasty, lens status,intraocular pressure at the time of presentation, and the timeof diagnosis of glaucoma were noted. The mean intraocularpressure was 35.5 &#x000b1; 5.8 mm Hg (range, 26-52 mm Hg). Themean time of follow-up after penetrating keratoplasty was6.97 &#x000b1; 2.98 months (range, 2-16 months). Of the 31 patients,11 had undergone penetrating keratoplasty for therapeuticpurposes (infectious keratitis), whereas the remaining 20had undergone keratoplasty for optical reasons. Fourteen(45.1%) patients were pseudophakic, 13 (41.9%) wereaphakic, and 4 (12.9%) were phakic. The types of synechiaenoted on the UBM included peripheral anterior synechiaein 30/31 (96.7%) eyes [<xref ref-type="fig" rid="F2">Fig. 2</xref>], synechiae at the graft host junction in13/31 (41.93%) eyes [<xref ref-type="fig" rid="F3">Fig. 3</xref>], both peripheral anterior synechiae andgraft. Host junction synechiae in 12/31 (38.7%) eyes [<xref ref-type="fig" rid="F4">Fig. 4</xref>], centralirido-corneal synechiae in 6/31 (19.3%) eyes [<xref ref-type="fig" rid="F5">Fig. 5</xref>], and intraocularlens iris synechiae in 3/31 (9.6%) eyes. [<xref ref-type="fig" rid="F6">Fig. 6</xref>]. This study concludedthat secondary angle closure caused by anterior synechiaeformation is one of the important causes for PPKG in eyeswith opaque grafts. UBM, therefore, serves as a useful toolfor anterior segment evaluation in such cases and can helpin planning the site for glaucoma filtering surgeries anddrainage devices.</p></sec></sec><sec sec-type=""><title>Management</title><p>Management of post-PK glaucoma (Appendix) is a complexissue and requires an insight into the pathophysiologyleading to elevated IOP. It is important to take appropriatesteps during surgery for primary prevention of this blindingdisorder.</p><sec><title>Prophylaxis</title><sec><title>Preoperative factors</title><p>Pre-existing glaucoma is a major risk factor for post-operativeglaucoma and graft failure and is especially difficult to treat inaphakic and pseudophakic eyes.<xref ref-type="bibr" rid="ref18">18</xref>-<xref ref-type="bibr" rid="ref20">20</xref> Reinhard<italic>et al</italic>.<xref ref-type="bibr" rid="ref19">19</xref> estimatedthe 3-year graft survival rate in patients with a pre-operativehistory of glaucoma to be 71%, in contrast to 89% without sucha history. A high incidence of graft failure has been reportedif a glaucoma operation is performed following the PK.<xref ref-type="bibr" rid="ref21">21</xref>Some studies therefore suggest treating the glaucoma withmitomycin-C trabeculectomy<xref ref-type="bibr" rid="ref22">22</xref> or with a GDD<xref ref-type="bibr" rid="ref23">23</xref> combinedwith the PK surgery.</p></sec><sec><title>Intraoperative factors</title><p>During surgery, use of following procedures may reduce therisk for post-PK glaucoma: one-mm oversize donor button,<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref>deep bites,<xref ref-type="bibr" rid="ref10">10</xref> goniosynechiolysis, iridoplasty (iris tighteningprocedure) - [<xref ref-type="fig" rid="F7">Fig. 7</xref>] in cases of a floppy iris,<xref ref-type="bibr" rid="ref13">13</xref>viscoelastic removal at the end of surgery, and careful wound closure toprevent post-operative wound leaks.</p></sec><sec><title>Post-operative factors</title><p>Post-operatively, judicious use of topical steroids controls theinflammation and prevents PAS formation. Cycloplegics keepthe pupil mobile and prevent pupillary block glaucoma. TheIOP must be monitored as long-term use of steroid therapy canlead to secondary open angle glaucoma.</p></sec></sec><sec><title>Medical management</title><p>Use of topical medications to control IOP is still the first-linetreatment of post-PK glaucoma. The following medicationscan be used:</p><p>Beta adrenergic blockers (timolol and betaxolol), alpha-2-adrenergic agonists (brimonidine), miotics (pilocarpine),prostaglandin analogs (latanoprost, travoprost, andbimatoprost), and carbonic anhydrase inhibitors (acetazolamideand methazolamide).</p><p>Beta adrenergic blocking agents and adrenergic agonistsact by decreasing aqueous humor production having no effecton outflow pathways. Adrenergic agents are rarely used incurrent practice, as they are not very effective and causechronic conjunctival inflammation. Brimonidine tartarate 0.2%or 0.15% with purite preservative can be used (thrice dailyas monotherapy and twice daily as combination therapy).Apraclonidine (0.5%) is a potent vasoconstrictor and is usefulboth to prevent AC bleeding during the operation and to treatresultant IOP spikes post-operatively from such a bleed. Mioticshave little effect in the presence of angle closure caused by PASand are no longer recommended.</p><p>Systemic carbonic anhydrase inhibitors are very useful as ashort-term therapy in the early post-operative period to controlthe IOP. Long-term therapy is limited by serious side effects suchas tinnitus, nausea, gastrointestinal disturbances, paresthesias,fatigue, depression, anorexia, weight loss, nephrolithiasis,and blood dyscrasias.<xref ref-type="bibr" rid="ref26">26</xref> Topical carbonic anhydrase inhibitors(dorzolamide and brinzolamide) should be used with cautionas they also suppress the carbonic anhydrase enzyme in thecorneal endothelium and long-term use can lead to graftdecompensation.<xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref> Although these groups of drugscan be safely used in healthy grafts with good endothelial reserve,their use for a long period of time should be avoided in caseswith marginal endothelial reserve.</p><p>Prostaglandin analogs can also be used to decrease IOP byincreasing uveoscleral outflow and can be used in conjunctionwith beta blockers. Preservatives, such as benzalkonium chloride(BAC; 0.01%) used in majority of topical antiglaucoma medication,have a toxic effect on corneal epithelium and one should try anduse preservative free unims for long-term therapy.</p><p>When using topical drugs to lower the IOP, one has tokeep in mind the side effects that are peculiar to them in thesetting of post-PK glaucoma. Beta adrenergic blockers canlead to superficial punctate keratopathy, exacerbation of dryeye, and corneal anesthesia all of which by themselves canbe detrimental to the state of the graft. Alpha-2-adrenergicagonist drugs can lead to allergic periocular reactions, besidessuperficial punctate keratopathy and dry eyes. The use ofmiotics in this setting is discouraged, because they promotebreakdown of blood aqueous barrier, thus stimulating graftrejection and increasing the risk of retinal detachment,particularly in aphakes. The prolonged use of topical carbonicanhydrase inhibitors can lead to graft decompensation in thepresence of borderline corneal endothelial status. Finally,the prostaglandin analogs should also be used with cautionas they may lead to uveitis, cystoid macular edema (CME)in aphakia and pseudophakia, and reactivation of herpessimplex keratitis in patients grafted with a previous historyof healed herpetic keratitis. The use of adrenergic agents likeepinephrine, dipivefrin is also discouraged in the modernday management of these patients because of their potentialcorneal epithelial toxicity, exacerbation of CME in aphakes,pseudophakes and promotion of conjunctival inflammationthereby making future surgical intervention all the moredifficult.</p><p>In cases of steroid responsive glaucoma, the dose of steroiddrops may be tapered to the minimum required. Alternatively,stronger steroid drops can be replaced by steroids that haveless tendency to increase IOP such as topical fluorometholone,loteprednol, and rimexolone. Cyclosporine A 0.5-2.0% topicaldrops four times daily can be substituted for steroids and thiscan also help to control the IOP.<xref ref-type="bibr" rid="ref29">29</xref></p></sec><sec><title>Surgical management</title><p>The following options are available:</p><p><list list-type="bullet"><list-item><p>Laser trabeculoplasty</p></list-item><list-item><p>Laser iridoplasty/iridotomy</p></list-item><list-item><p>Trabeculectomy with antimetabolites</p></list-item><list-item><p>GDDs</p></list-item></list></p><sec><title>Laser trabeculoplasty</title><p>Argon laser trabeculoplasty (ALT) can be used if the angleis open. Recommended settings are a 50-&#x000b5; spot size, 0.1-secduration, and 600-900 mW of power.<xref ref-type="bibr" rid="ref30">30</xref> The laser is aimed atthe junction of the pigmented and non-pigmented trabecularmeshwork and the end point is minimal blanching or bubbleformation. Complications are post-operative IOP spikes anduveitis, which can trigger graft rejection. It is imperative to givepost-laser topical steroids at an increased frequency (two to fourhourly) to minimize the chances of triggering graft rejection.ALT may be indicated in patients with open angles, clear grafts,and moderately elevated IOP (20-25 mmHg) on glaucomamedications. Diode laser trabeculoplasty and selective lasertrabeculoplasty may also be used.</p><p>Laser iridotomy may be performed with an Nd:YAG(neodymium:yttrium-aluminium-garnet) laser, if a pupillaryblock is suspected. Gonioplasty can be done for PAS, whichhas been present for less than one year.</p></sec><sec><title>Trabeculectomy</title><p>Conventional trabeculectomy is usually not effective dueto dense perilimbal scarring and fibrosis with an increasedrisk of failure. The failure rate is further increased inaphakic eyes where it is mandatory to do a vitrectomy toprevent any vitreous from blocking the trabeculectomy ostium.Antimetabolites (5-fluorouracil and mitomycin-C) must be usedin these patients to inhibit the fibroblastic response.<xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref31">31</xref> Five milligrams of 5 FU in 0.1 cc is given daily as a subconjunctivalinjection in the immediate post-operative period for 7-10 days.<xref ref-type="bibr" rid="ref31">31</xref>Apart from the inconvenience of daily injections, 5-FUinjections are associated with a high rate of corneal epithelialtoxicity and therefore should be used with caution in patientswith post-PK glaucoma.</p><p>Mitomycin-C application (0.2-0.4 mg applied for 1-4 minsubconjunctival or sub-scleral) has significantly improved thesuccess rate of filtering surgery for glaucoma.<xref ref-type="bibr" rid="ref31">31</xref></p><p>The reported success rate in IOP control with mitomycintrabeculectomy in patients with post-PK glaucoma is 67-91%and that of graft failure is 12-18%.<xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref>Intraoperative care must be taken to prevent shallowing of AC to minimize endothelialloss, and mitomycin-C should be thoroughly washed off priorto entry into the AC.</p></sec><sec><title>Glaucoma drainage devices</title><p>Glaucoma drainage devices create an alternate aqueouspathway by channeling aqueous from the AC through a longtube to an equatorial plate that promotes bleb formation. In1987, Kirkness was the first to report the use of GDD in post-PK glaucoma.<xref ref-type="bibr" rid="ref34">34</xref> Although the use of GDDs appears to controlglaucoma in a high percentage of patients in all publishedseries (71-96%, with an average of 84.8%), it appears to beassociated with a high incidence of graft failure in the rangeof 10-51% (average 36.2%).<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref37">37</xref>-<xref ref-type="bibr" rid="ref39">39</xref> The risk of graft rejectionmay be increased after GDD surgery, because the drainagetube may provide a conduit for retrograde passage ofinflammatory cells into the AC. It is important to note thatthe risk of graft rejection following the insertion of any GDDwhether valved or non-valved is similar. This implies thatother mechanisms besides passage of inflammatory cells intothe AC through the tube may play a role. Inflammation causedby the surgical procedure itself may lead to post-surgicaluveitis and breakdown of blood aqueous barrier, triggeringgraft rejection.</p><p>The etiology of graft failure probably is multifactorial.The presence of underlying chronic inflammation, extensivePAS, and multiple previous surgeries may compromise thegraft. It has been seen that most corneal transplants undergoa 60% reduction in the central endothelial cell count duringthe first two post-operative years after implant surgery.<xref ref-type="bibr" rid="ref35">35</xref> Thecomplication associated with GDDs like shallow AC with iris/tube graft endothelial touch might accelerate the process leadingto graft failure. Meticulous surgery should be done to avoidthe complication of flat AC and tube endothelial touch. Theuse of high-dose steroids for 3-6 months in the post-operativephase may help in controlling and suppressing inflammation.Other complications include conjunctival erosion, prolongedhypotony, tube endothelial touch, tube obstruction, tube failure,retinal detachment, tube plate extrusion, epithelial downgrowth, and infection.</p><p>There are two types of GDDs, which can be used: (i) valved -offers resistance to out flow (Ahmed valve; Krupin implant);(ii) valveless - no resistance to out flow (Molteno implant,Baerveldt implant). The advantages of the valved devices,especially that of the Ahmed glaucoma valve,<xref ref-type="bibr" rid="ref36">36</xref> is the ease ofinsertion and low incidence of hypotony in the immediatepost-operative phase. However, the Ahmed valve is associatedwith a high incidence of increased IOP - hypertensive phase(as much as 80%), 1-3 months after the operation, which mayneed needling and 5-FU injections.<xref ref-type="bibr" rid="ref36">36</xref> On the other hand, GDDswith a larger surface area, such as the double-plate Moltenoand Baerveldt implant, appear to exhibit a lesser incidence ofthe hypertensive phase and may achieve slightly lower IOPs inthe long term. The overall success rate and other complications,including corneal decompensation, appear to be similar amongall GDDs.<xref ref-type="bibr" rid="ref37">37</xref>-<xref ref-type="bibr" rid="ref39">39</xref></p><p>It is preferred to use the Ahmed glaucoma valve in patientswith mild-to-moderate glaucomatous optic nerve damage andlarger surface area devices, such as the double-plate Moltenoand the Baerveldt implant, which are associated with moresignificant pressure reduction in patients with more advancedoptic nerve damage.</p></sec></sec><sec><title>Cyclodestructive procedures</title><p>Cyclodestructive procedures aim to control the IOP by decreasingaqueous humor production by destroying part of the ciliarybody. Cyclocryotherapy, transscleral cyclophotocoagulationwith diode or krypton laser are the various procedures that canbe performed on patients with intractable post-PK glaucoma.Since conventional filtering surgeries and GDDs have a highfailure rate, cyclophotocoagulation is a widely adoptedprocedure, because it is non-invasive and can be done as alow-cost outpatient procedure.</p><p><bold>Cyclocryotherapy</bold> has been a principal mode of treatmentof post-PK glaucoma. The glaucoma cryoprobe is placed for1 min, 1.5 mm behind the corneoscleral limbus. A total of6-8 applications are made with equidistant spots, involvingthe inferior 180&#x000b0; or 270&#x000b0; circumference of the globe at atemperature of &#x02212;60&#x000b0;C to &#x02212;80&#x000b0;C. Two to three clock-hours ofthe superior quadrant of the globe should be left untreatedto allow for a future filtering surgery procedure. Thetreatment can be repeated if indicated. Complications of thisprocedure include uveitis, immediate rise in IOP, graft failure,corneal decompensation, macular edema, cataract, vitreoushemorrhage, and phthisis bulbi.</p><p><bold>Nd:YAG laser cyclophotocoagulation</bold><xref ref-type="bibr" rid="ref40">40</xref> involves the use of15 evenly spaced burns, placed 1-1.5 mm from the limbus for180&#x000b0; with a Nd:YAG laser.<xref ref-type="bibr" rid="ref37">37</xref> The recommended mean energylevel is 4.0-9.0 J. Post-operative pain medication and topicalsteroids are indicated. Low energy settings are preferred inpatients previously treated with cyclocryotherapy or filteringprocedure to avoid hypotony. Repeated applications may benecessary before adequate control is achieved.</p><p><bold>Diode laser cyclophotocoagulation</bold><xref ref-type="bibr" rid="ref41">41</xref> utilizes asemiconductor diode laser with a wave length of 810 nm, haslower scleral transmission than the Nd:YAG laser (1064 nm)but greater absorption by melanin. As semiconductor diodeshave solid-state construction, they have the advantage ofportability, durability, and smaller size as compared withNd:YAG lasers. The recommended power settings withthe diode laser are 1250-2000 mW, with a 2-sec exposuretime. An initial power setting of 1500 mW is increased ordecreased by 250-mW increments until it is 250 mW belowthat producing an audible popping sound. Complicationsinclude decrease in the Snellen visual acuity (22-56%), graftfailure (11-65%), persistent hypotony (5-10%), anterior uveitis,epithelial defects, and loss of vision, severe pain, phthisisbulbi, hyphema, hypotony, intractable pain, sympatheticophthalmia, scleral thinning, and vitreous hemorrhage. It isrecommended to avoid the 3 and 9 o&#x02032;clock positions to sparethe ciliary nerves.</p><p><bold>Transpupillary argon laser photocoagulation</bold><xref ref-type="bibr" rid="ref42">42</xref> is anothermodality that can be used. It has been seen that transpupillaryargon laser photocoagulation of the ciliary process can reduceIOP in direct proportion to the number of ciliary processesablated. The technique requires a Goldmann three-mirror lens.The laser is set at 50-100 &#x000b5;m spot size for a duration of 0.1-0.2 secand with a power of 1000 mW. Hemostasis is obtained withrepeated application of the laser with larger (200 &#x000b5;m) spot size,0.2-sec duration, and lower power (250 mW). Ciliary processesare ablated one at a time. A limiting factor of transpupillaryargon laser cyclophotocoagulation is the visualization of theprocesses requiring widely dilated pupil and specializedcontact lens. Endoscopic cyclophotocoagulation<xref ref-type="bibr" rid="ref43">43</xref> is anothertechnique that can be used.</p></sec></sec><sec sec-type=""><title>Prognosis of Post-PK Glaucoma</title><p>Two things that are important in managing a case of post-PKglaucoma are the influence of glaucoma on graft survivaland the effect of glaucoma in causing permanent irreversiblevisual loss. There is uniform agreement in literature regardingadverse outcomes on both of the above accounts. A studyfrom our center based on a retrospective review of 747 PKsreported only 50% graft clarity over the study period<xref ref-type="bibr" rid="ref18">18</xref> andfurther worse only 19% of eyes could retain a visual acuityof 20/60 or better despite medical and surgical measuresto control the glaucoma. One thing that needs to be keptin the mind while managing a case of post-PK glaucomais that the PAS formation is progressive over time andthat IOP control might worsen over long-term follow-up.Therefore, long-term vigilance is required in taking care ofsuch eyes. Another issue that is important is the effect of anyintervention on triggering graft rejection and subsequentlygraft failure. Kwon <italic>et al</italic>.,<xref ref-type="bibr" rid="ref39">39</xref> in their 3-year retrospective study,documented 44% graft rejection and non-immunologiccauses of graft failure following insertion of GDDs in sucheyes. Shah <italic>et al.</italic><xref ref-type="bibr" rid="ref41">41</xref> determined the visual outcome after diodelaser cyclophotocoagulation in 28 eyes with at least 6-monthfollow-up. They documented stable baseline visual acuityin 17 of the 28 (61%) patients and worsening in eight of the28 (28%) patients.</p></sec><sec sec-type=""><title>Conclusion</title><p>Uncontrolled IOP after PK is one of the leading causes ofgraft failure and visual loss in this patient population. Itis mandatory that the IOP is monitored on a regular basisafter corneal transplantation and aggressively treated iffound high. Any patient with pre-existing glaucoma mustbe carefully evaluated prior to the corneal transplants.Optimal surveillance and aggressive medical and surgicalmanagement can salvage both graft and vision in these alreadycompromised eyes.</p></sec></body><back><fn-group><fn><p>Source of Support: Nil</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulks</surname><given-names>GN</given-names></name></person-group><article-title>Glaucoma associated with penetrating keratoplasty</article-title><source>Ophthalmology</source><year>1987</year><volume>94</volume><fpage>871</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">3309771</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>SE</given-names></name><name><surname>Kaufman</surname><given-names>HE</given-names></name></person-group><article-title>Graft failure after penetrating keratoplasty</article-title><source>Surv Ophthalmol</source><year>1990</year><volume>34</volume><fpage>325</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">2183380</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>DB</given-names></name><name><surname>Schanzlin</surname><given-names>DJ</given-names></name><name><surname>Brown</surname><given-names>SI</given-names></name></person-group><article-title>Incidence of increasedintraocular pressure after keratolasty</article-title><source>Am J Ophthalmol</source><year>1981</year><volume>92</volume><fpage>372</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7027797</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayyala</surname><given-names>RS</given-names></name></person-group><article-title>Penetrating keratoplasty and glaucoma</article-title><source>Surv Ophthalmol</source><year>2000</year><volume>45</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">11033036</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>AR</given-names></name><name><surname>Kaufman</surname><given-names>HE</given-names></name></person-group><article-title>Intraocular pressure following penetrating keratoplasty</article-title><source>Am J Ophthalmol</source><year>1969</year><volume>68</volume><fpage>835</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">4900892</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karesh</surname><given-names>JW</given-names></name><name><surname>Nirankari</surname><given-names>VS</given-names></name></person-group><article-title>Factors associated with glaucoma after penetrating keratoplasty</article-title><source>Am J Ophthalmol</source><year>1983</year><volume>96</volume><fpage>160</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">6349367</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>AM</given-names></name><name><surname>Schimdt</surname><given-names>CM</given-names></name><name><surname>Cohen</surname><given-names>E</given-names></name></person-group><article-title>Glaucoma in the immediate post operative period after penetrating keratoplasty</article-title><source>Am J Ophthalmol</source><year>1993</year><volume>115</volume><fpage>711</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8506905</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>RJ</given-names></name><name><surname>Kaufman</surname><given-names>HE</given-names></name></person-group><article-title>A mathematical description of causative factors and prevention of elevated intraocular pressure afterkeratoplasty</article-title><source>Invest Ophthalmol Vis Sci</source><year>1977</year><volume>16</volume><fpage>1085</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">336579</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkness</surname><given-names>CM</given-names></name><name><surname>Moshegov</surname><given-names>C</given-names></name></person-group><article-title>Post keratoplasty glaucoma</article-title><source>Eye</source><year>1988</year><volume>2</volume><fpage>19</fpage><lpage>26</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>TJ</given-names></name><name><surname>Krupin</surname><given-names>T</given-names></name><name><surname>Grodzki</surname><given-names>W</given-names></name></person-group><article-title>the effect of suture depth on outflow facility in penetrating keratoplasty</article-title><source>Arch Ophthalmol</source><year>1978</year><volume>96</volume><fpage>505</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">343768</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>TJ</given-names></name><name><surname>Olson</surname><given-names>RJ</given-names></name><name><surname>Waltman</surname><given-names>S</given-names></name><name><surname>Kaufman</surname><given-names>H</given-names></name></person-group><article-title>Transplant size and elevated intraocular pressure: Postkeratoplasty</article-title><source>Arch Ophthalmol</source><year>1978</year><volume>96</volume><fpage>2231</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">363108</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lass</surname><given-names>JH</given-names></name><name><surname>Pavan-Langston</surname><given-names>D</given-names></name></person-group><article-title>Timolol therapy in secondary angle closure glaucoma post penetrating keratoplasty</article-title><source>Ophthalmology</source><year>1979</year><volume>86</volume><fpage>54</fpage><lpage>9</lpage></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>EJ</given-names></name><name><surname>Kenyon</surname><given-names>KR</given-names></name><name><surname>Dohlmam</surname><given-names>CH</given-names></name></person-group><article-title>Iridoplasty for prevention of post keratoplasty angle closure glaucoma</article-title><source>Ophthalmic Surg</source><year>1982</year><volume>13</volume><fpage>994</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6761618</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMillan</surname><given-names>F</given-names></name><name><surname>Forster</surname><given-names>RK</given-names></name></person-group><article-title>Comparison of MacKay-Marg, Goldmannand Perkins&#x02032; tonometers in abnormal corneas</article-title><source>Arch Ophthalmol</source><year>1975</year><volume>93</volume><fpage>420</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">805582</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doughty</surname><given-names>MJ</given-names></name><name><surname>Zaman</surname><given-names>ML</given-names></name></person-group><article-title>Human corneal thickness and its impact on intraocular measures: A review and meta-analysis approach</article-title><source>Surv Ophthalmol</source><year>2000</year><volume>44</volume><fpage>367</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">10734239</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinfeld</surname><given-names>RS</given-names></name><name><surname>Cohen</surname><given-names>EJ</given-names></name><name><surname>Laibson</surname><given-names>PR</given-names></name></person-group><article-title>The accuracy of finger tension for estimating intraocular pressure after penetrating keratoplasty</article-title><source>Ophthalmic Surg Lasers</source><year>1998</year><volume>29</volume><fpage>213</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9547775</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dada</surname><given-names>T</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Vanathi</surname><given-names>M</given-names></name><name><surname>Gadia</surname><given-names>R</given-names></name><name><surname>Panda</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><etal/></person-group><article-title>Ultrasound biomicroscopy in opaque grafts with post-penetrating keratoplasty glaucoma</article-title><source>Cornea</source><year>2008</year><volume>27</volume><fpage>402</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18434841</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sihota</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Panda</surname><given-names>A</given-names></name><name><surname>Aggarwal</surname><given-names>HC</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name></person-group><article-title>Post penetrating keratoplasty glaucoma: Risk factors, management and visual outcome</article-title><source>Aust NZJ Ophthalmol</source><year>1998</year><volume>26</volume><fpage>305</fpage><lpage>9</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhard</surname><given-names>T</given-names></name><name><surname>Kallmann</surname><given-names>C</given-names></name><name><surname>Cepin</surname><given-names>A</given-names></name></person-group><article-title>The influence of glaucoma history on raft survival after penetrating keratoplasty</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>1997</year><volume>235</volume><fpage>553</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9342604</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagami</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Tsuru</surname><given-names>T</given-names></name></person-group><article-title>Risk factors for graft failure in penetrating keratoplasty</article-title><source>Acta Ophthalmol Scand</source><year>1996</year><volume>74</volume><fpage>584</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9017047</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkness</surname><given-names>CM</given-names></name><name><surname>Steele</surname><given-names>AD</given-names></name><name><surname>Ficker</surname><given-names>LA</given-names></name></person-group><article-title>Coexistent corneal disease andglaucoma managed by either drainage surgery and subsequentkeratoplasty or combined drainage surgery and penetratingkeratoplasty</article-title><source>Br J Ophthalmol</source><year>1992</year><volume>76</volume><fpage>146</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">1540557</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figuerido</surname><given-names>RS</given-names></name><name><surname>Araujo</surname><given-names>SV</given-names></name><name><surname>Cohen</surname><given-names>EJ</given-names></name></person-group><article-title>Management of coexistingcorneal disease and glaucoma by combined penetratingkeratoplasty and trabeculectomy with mitomycin C</article-title><source>Ophthalmic Surg Lasers</source><year>1996</year><volume>27</volume><fpage>903</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8938797</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapuano</surname><given-names>CJ</given-names></name><name><surname>Schimdt</surname><given-names>CM</given-names></name><name><surname>Cohen</surname><given-names>EJ</given-names></name></person-group><article-title>Results of alloplastic tubeshunt procedures before, during, or after penetrating keratoplasty</article-title><source>Cornea</source><year>1995</year><volume>14</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">7712732</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourne</surname><given-names>WM</given-names></name><name><surname>Davison</surname><given-names>JA</given-names></name></person-group><article-title>The effects of oversize donor buttonson post operative intraocular pressure and corneal curvature inaphakic penetrating keratoplasty</article-title><source>Ophthalmology</source><year>1982</year><volume>89</volume><fpage>242</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7045764</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vajpayee</surname><given-names>RB</given-names></name><name><surname>Dada</surname><given-names>T</given-names></name><name><surname>Ray</surname><given-names>M</given-names></name><name><surname>Tandon</surname><given-names>R</given-names></name><name><surname>Sethi</surname><given-names>A</given-names></name><name><surname>Turaka</surname><given-names>K</given-names></name></person-group><article-title>Oversized corneal grafts for corneal opacities with iridocornealadhesions</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>2026</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11713073</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>DL</given-names></name><name><surname>Bramsen</surname><given-names>T</given-names></name><name><surname>Sperling</surname><given-names>S</given-names></name></person-group><article-title>Carbonic anhydrase inhibitorside effects. Serum chemical analysis</article-title><source>Arch Ophthalmol</source><year>1977</year><volume>95</volume><fpage>1378</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">889513</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konowal</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>SV</given-names></name></person-group><article-title>Irreversible cornealdecompensation in patients treated with dorzolamide</article-title><source>Am J Ophthalmol</source><year>1999</year><volume>127</volume><fpage>403</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10218692</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fraunfelder</surname><given-names>FT</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mever</surname><given-names>SM</given-names></name></person-group><article-title>Drugs used primarily in Ophthalmology</article-title><source>Drug induced Ocular side effects and Drug interactions</source><year>1989</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lea and Febiger</publisher-name><fpage>476</fpage><lpage>7</lpage></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>HD</given-names></name><name><surname>Donnenfeld</surname><given-names>ED</given-names></name><name><surname>Kanellopoulos</surname><given-names>AJ</given-names></name><name><surname>Grossman</surname><given-names>GA</given-names></name></person-group><article-title>Topical cyclosporine A in the management of postkeratoplastyglaucoma</article-title><source>Cornea</source><year>1997</year><volume>16</volume><fpage>284</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9143799</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van meter</surname><given-names>WS</given-names></name><name><surname>Allen</surname><given-names>RC</given-names></name><name><surname>Waring</surname><given-names>CO</given-names></name></person-group><article-title>Laser trabeculoplasty forglaucoma in aphakia and pseudophakic eyes after penetratingkeratoplasty</article-title><source>Arch Ophthalmol</source><year>1988</year><volume>106</volume><fpage>185</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3277605</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skuta</surname><given-names>GI</given-names></name><name><surname>Beeson</surname><given-names>CC</given-names></name><name><surname>Higginbotham</surname><given-names>EJ</given-names></name></person-group><article-title>Intraoperative mitomycin Cversus post operative 5-flurouracil in high risk glaucoma filtrationsurgery</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>438</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">1565457</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowers</surname><given-names>I</given-names></name><name><surname>Ticho</surname><given-names>U</given-names></name></person-group><article-title>Mitomycin-C in combined or two stageprocedure trabeculectomy followed by penetrating keratoplasty</article-title><source>J Glaucoma</source><year>1999</year><volume>8</volume><fpage>184</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10376258</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayyala</surname><given-names>RS</given-names></name><name><surname>Pieroth</surname><given-names>L</given-names></name><name><surname>Vinals</surname><given-names>AF</given-names></name></person-group><article-title>Comparison of mitomycin Ctrabeculectomy, glaucoma drainage device implantation and laserneodymium YAG cyclophotocoagulation in the management ofintractable glaucoma after penetrating keratoplasty</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>1550</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9709773</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkness</surname><given-names>CM</given-names></name></person-group><article-title>Penetrating keratoplasty, glaucoma and silicondrainage tubing</article-title><source>Dev Ophthalmol</source><year>1987</year><volume>14</volume><fpage>161</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">3308553</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>AK</given-names></name><name><surname>Hiorns</surname><given-names>RW</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name></person-group><article-title>Modeling of changes in the cornealendothelium after cataract surgery and penetrating keratoplasty</article-title><source>Br J Ophthalmol</source><year>1992</year><volume>76</volume><fpage>32</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1739688</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayyala</surname><given-names>RS</given-names></name><name><surname>Zurakowski</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name></person-group><article-title>A clinical study ofAhmed valve implant in advanced glaucoma</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>1968</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">9787371</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdulla</surname><given-names>Al-Torbak</given-names></name></person-group><article-title>Graft survival glaucoma outcome aftersimultaneous penetrating keratoplasty and Ahmed glaucoma valveimplant</article-title><source>Cornea</source><year>2003</year><volume>22</volume><fpage>194</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12658081</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidoti</surname><given-names>PA</given-names></name><name><surname>Mosny</surname><given-names>AY</given-names></name><name><surname>Ritterband</surname><given-names>DC</given-names></name><name><surname>Seeder</surname><given-names>JA</given-names></name></person-group><article-title>Pars planatube insertion of glaucoma drainage implants and penetratingkeratoplasty in patients with coexisting glaucoma and cornealdisease</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>1050</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11382628</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>YH</given-names></name><name><surname>Taylor</surname><given-names>JM</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Honkanen</surname><given-names>RA</given-names></name><name><surname>Zimmerman</surname><given-names>MB</given-names></name><name><surname>Alward</surname><given-names>WL</given-names></name><etal/></person-group><article-title>Long term results of eyes with penetratingkeratoplasty and glaucoma drainage tube implant</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>272</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11158798</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Threlkeld</surname><given-names>AB</given-names></name><name><surname>Shields</surname><given-names>MB</given-names></name></person-group><article-title>Noncontact transscleral Nd: YAGcyclophotocoagulation for glaucoma after penetrating keratoplasty</article-title><source>Am J Ophthalmol</source><year>1995</year><volume>120</volume><fpage>569</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">7485358</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>GA</given-names></name><name><surname>Kirwan</surname><given-names>JK</given-names></name><name><surname>Bunce</surname><given-names>C</given-names></name><name><surname>Bloom</surname><given-names>PA</given-names></name><name><surname>Ficker</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Cyclodiode photocoagulation for refractory glaucoma afterpenetrating keratoplasty</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>1986</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11713066</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holz</surname><given-names>HA</given-names></name><name><surname>Lim</surname><given-names>MC</given-names></name></person-group><article-title>Glaucoma lasers: A review of the newertechniques</article-title><source>Curr Opin Ophthalmol</source><year>2005</year><volume>16</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">15744138</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><article-title>Endoscopic cyclophotocoagulation</article-title><source>Br J Ophthalmol</source><year>2002</year><volume>86</volume><fpage>1434</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12446381</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>(A) Graft corneal edema due to peripheral anterior synechiae (PAS) and secondary glaucoma. (B) PAS - gonioscopic view</p></caption><alt-text>Figure 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>PAS on ultrasound biomicroscopy (UBM) (copyright ownerLippincott, Williams and Wilkins, 2008)</p></caption><alt-text>Figure 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Graft host junction (GH Jn) synechia on UBM (copyrightowner Lippincott, Williams and Wilkins, 2008)</p></caption><alt-text>Figure 3</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Both PAS and GH Jn synechiae (copyright owner Lippincott,Williams and Wilkins, 2008)</p></caption><alt-text>Figure 4</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p>Central iris corneal synechia with ACIOL tilt (copyright ownerLippincott, Williams and Wilkins, 2008)</p></caption><alt-text>Figure 5</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p>IOL iris synechia (copyright owner Lippincott, Williams andWilkins, 2008)</p></caption><alt-text>Figure 6</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><p>PK with concomitant iridoplasty (courtesy of Dr. NamrataSharma, Dr. R.P. Centre)</p></caption><alt-text>Figure 7</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g007"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Indications for penetrating keratoplasty and associated rates of chronic post-PK glaucoma</p></caption><alt-text>Table 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g008"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Mechanisms of increased intraocular pressure after penetrating keratoplasty</p></caption><alt-text>Table 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-269-g009"/></table-wrap></floats-group></article>